Temsirolimus Adventitial Delivery to Improve ANGiographic Outcomes Below the Knee.
Ian CawichEhrin J ArmstrongJon C GeorgeJaafer GolzarMehdi H ShishehborMahmood RazaviVictoria LeeKenneth OurielPublished in: Journal of endovascular therapy : an official journal of the International Society of Endovascular Specialists (2022)
There remain gaps in the endovascular treatment of patients with atherosclerotic lesions of below-the-knee (BTK) arteries. The TANGO trial evaluated the use of sub-adventitial temsirolimus with the Bullfrog micro-infusion device during BTK interventions. The therapy was safe and effective. Compared with controls, vessel lumen area patency was improved, and target lesion failure was less frequent. The effects were most appreciable in subjects with higher baseline TASC lesions (B, C, or D). Sub-adventitial temsirolimus offers the potential to improve the results of BTK interventions in this challenging patient population.
Keyphrases
- tyrosine kinase
- endovascular treatment
- total knee arthroplasty
- physical activity
- knee osteoarthritis
- anterior cruciate ligament
- anterior cruciate ligament reconstruction
- clinical trial
- case report
- study protocol
- low dose
- phase iii
- ultrasound guided
- randomized controlled trial
- stem cells
- type diabetes
- human health
- mesenchymal stem cells
- insulin resistance
- adipose tissue
- cell therapy
- bone marrow
- glycemic control